Published in TB and Outbreaks Week, December 1st, 2009
Immune Targeting Systems is developing vaccines for mutating viruses. The lead candidate (FP-01) is a synthetic vaccine against all potential seasonal and pandemic influenza strains. This will eliminate the need to remanufacture the vaccine each year in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.